

## 2022 U.S. Monkeypox Outbreak Short Case Report Form

Instructions for State, Local, and Territorial Health Jurisdictions: This form is an aid for public health officials when collecting essential data elements needed for investigating and reporting probable or confirmed Monkeypox cases to CDC as part of the 2022 U.S. Monkeypox Outbreak response. Local public health officials may choose to use this fillable PDF for data collection within their jurisdiction, but data submission to CDC should be through established case surveillance systems and not through individually completed forms. Case information should always be captured electronically to minimize transcription errors, however this form may be printed if needed.

Please visit the CDC Website for the latest public health information about monkeypox: www.cdc.gov/monkeypox

Note: This form is to be administered to the patient or their proxy—if the patient is deceased, administer with their proxy and/or healthcare provider.

Form Approved
OMB No. 0920-1011
Exp. Date 01/31/2023
Short Case Report Form 2022 Monkeypox Outbreak

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

6/30/2022 Page 1 of 10



State-assigned case ID:
State/Territory of Residence:
Country of Parisland
County of Residence:
You mentioned you reside in a Tribal Area, please specify:
[FOR INTERVIEWER] Did the individual die from this illness?
Yes No Unknown
If deceased, date of death:
<u>Demographic Information</u>
What is your age, in years?
What is your race? (check all that apply) White
African American or Black
Asian
Native Hawaiian/Pacific Islander
American Indian/Alaska Native
Multiple Races
Unknown Race
Other
Declined to answer
If the selected race is American Indian or Alaska Native, what is the tribal affiliation?
If you selected other for race, please specify:



What is your ethnicity? (check one):

**Hispanic or Latino** 

Non-Hispanic or Latino

**Declined to answer** 

Unknown

Do you currently describe yourself as male, female, or transgender?

Male

**Female** 

**Transgender Female** 

**Transgender Male** 

Another gender identity

**Declined to answer** 

What sex were you assigned at birth, on your original birth certificate?

Male Female Declined to answer Unknown

[FOR INTERVIEWER] Did the individual ever receive a vaccine against smallpox?

Yes No Unknown

If yes, please give the reason, date, manufacturer, and dose number for each vaccine received:

	Reason	Vaccine Date	Vaccine Manufacturer	Dose Number
Vaccine 1	Pre-exposure Post-exposure Routine pre-exposure Unknown		MIP BN WAL	
Vaccine 2	Pre-exposure Post-exposure Routine pre-exposure Unknown		MIP BN WAL	
Vaccine 3	Pre-exposure Post-exposure Routine pre-exposure Unknown		MIP BN WAL	

<sup>\*</sup>MIP = Emergent Biosolutions (ACAM2000); BN = Bavarian Nordic A/S (JYNNEOS); WAL = Wyeth (DryVax - prior to 2008)

## **History of Possible Exposures**

Did you engage in any sex (e.g., vaginal, oral or anal sex) and/or close intimate contact (e.g., cuddling, kissing, touching partner's genitals or anus, or sharing sex toys) in the three weeks before your first symptom appeared (also called symptom onset)?

Yes

No

Unknown

If yes, indicated the number of partner(s) (including named and anonymous) below:

Sensitive but Unclassified

6/30/2022 Page 3 of 10



Male:				
Yes	No	Unknown		
If yes, number of	of Male part	tners or descrip	tion if n	o number is provided:
FOR INTERVIEV	VFR1: If indi	vidual is unable	⊣ e to snec	ify, provide a range of options for the number of male
partners:	venj. II ilial	vidda is diidbic	to spec	ny, provide a range of options for the number of male
1	2-4	5-9	10+	Refused to answer
Female:				
Yes	No	Unknown		
If yes, number of	of female pa	irtners or descr	ription if ¬	no number is provided:
[FOR INTERVIEV	VER]: If indi	vidual is unable	e to spec	ify, provide a range of options for the number of female
partners:	-		-	
1	2-4	5-9	10+	Refused to answer
Transgender Fe		_		
Yes	No	Unknown		
If yes, number o	of transgend	ler female part	ners or o	description if no number is provided:
[FOR INTERVIEV	VER]: If indi	vidual is unable	– e to spec	ify, provide a range of options for the number of transgender
female partners	:		-	
1	2-4	5-9	10+	Refused to answer
Transgender Ma				
Yes	No	Unknown		
If yes, number o	of transgend	ler male partne	ers or de T	scription if no number is provided:
[FOR INTERVIEV	VER]: If indi	vidual is unable	e to spec	ify, provide a range of options for the number of transgender
male partners:	_		-	
1	2-4	5-9	10+	Refused to answer
Other Gender Id	dentity:			
Yes	No	Unknown		
If yes, number o	of other gen	der identity pa	rtners o	r description if no number is provided:
[FOR INTERVIEV	VER]: If indi	vidual is unable	– e to spec	ify, provide a range of options for the number of other gender
identity partner	_			,
1	2-4	5-9	10+	Refused to answer



Unknown:			
Y	es No	Unknown	
If yes, plea		cify if this case is epidemiolog se ID(s) (if known) and contac Unknown	ically linked to another confirmed or probable case: t type:
If yes, plea unknown	ase provide CD	C assigned Case ID. Enter Inte	rnational if not a U.S. Case, or enter "unknown" if
If yes, plea	ase provide Sta	ate assigned Case ID.	
Contact ty	ne:		
=	=	o case – home setting	
In	direct contact	(e.g., shared sexual partners)	
			nate contact (e.g., cuddling, kissing, touching partner's
		, or sharing sex toys)	
		ensils, or dishes	
SI	hared towels,	bedding, or clothing	
SI	hared transpo	rtation (e.g., carpooling, riding	g a bus, rising a motorcycle, using a taxi, using Uber)
(s	pecify mode o	f transportation)	
SI	hared bathroo	ms (toilets, sinks, showers)	
Fa	ace-to-face co	ntact, not including intimate c	ontact (being within six feet for more than three hours of
a	n unmasked ca	se-patient without wearing,	at a minimum, a surgical mask)
н	ealth care wo	·ker	
lo	lentified air co	ntact	
0	ther		
If other, p	lease specify:		
symptom	-	hin the US) outside your home called symptom onset)? Unknown	e state or territory during the 3 weeks before your first
T'	C3 140	OHRHOWH	
States trav	veled to:		



Date of departure (MM/DD/YYYY):
Date of return (MM/DD/YYYY):
Did you have intimate or sexual contact with new partners on this trip?
Yes No Unknown
[FOR INTERVIEWER] Any additional comments on travel within the US that may be important:
Did you spend time in a country outside the US during the 3 weeks before your first symptom appeared (also called symptom onset)?
Yes No Unknown
Country traveled to
Country traveled to:
Date of departure (MM/DD/YYYY):
Date of return to US (MM/DD/YYYY):
Did you have any intimate or sexual contact with new partners on trip?
Yes No Unknown
[FOR INTERVIEWER] Any additional comments on travel outside the US that may be important?
[FOR INTERVIEWER] Is this individual a health care worker who was exposed at work?
Yes No Unknown
[FOR INTERVIEWER] Please provide the suspect location of exposure
International Domestic Air Travel Contact Other Unknown
[FOR INTERVIEWER] If other, please specify the suspect location of exposure.



large gathering,			tional details on the location of exposure (e.g., health care setting,
[FOR INTERVIEV or anonymous)	VER] Please	provide the num	ber of identified contacts this case may have exposed (either named
Diagnostic Tes	ting Inform	<u>iation</u>	
	y performed ember Lab	the testing? (ch	eck all that apply)
Comme	ercial Lab		
Acaden	nic/Hospital	Lab	
Unknov	wn		
Performing lab s	specimen ID	s (i.e. a laborato	ry generated number that identified the specimen related to this
What was the o	rthopox viru	us test result?	
OPX+	OP	X- Inco	nclusive
What was the to	ast result da	to?	
Wildt was the to	est result du		
Clinical Inform	ation		
What signs or sy	mptoms did	d you experience	during the course of your illness?:
Fever:			
Yes	No	Unknown	
Rash:			
Yes	No	Unknown	
Enlarged Lymph	Nodes:		
Yes	No	Unknown	
Pruritis (itching)			
Yes	No	Unknown	
Rectal Pain:		_	
Yes	No	Unknown	
Rectal Bleeding:			
Yes	No	Unknown	
Pus or blood on		11. 1	
Yes	No	Unknown	



Proctit	is:			
	Yes	No	Unknown	
Tenesn	nus/urgen	cy to defec	ate:	
	Yes	No	Unknown	
Heada	che:			
	Yes	No	Unknown	
Malais			llness or weakn	ess):
	Yes	No	Unknown	
Conjun	ctivitis:			
	Yes	No	Unknown	
Abdom	inal Pain:			
	Yes	No	Unknown	
Vomiti	ng or Naus		University	
	Yes	No	Unknown	
Myalgi	a (muscle	-	University	
	Yes	No	Unknown	
Chills:	Yes	No	Unknown	
	162	NO	Olikilowii	
				(the date any symptoms mentioned above first started)?
Did you	u have a ra Yes	_	he course of yo nknown	ur illness?
If yes, v	what was t	the date of	rash onset (in o	ther words, the date the rash first appeared)?
				Unknown
If yes, \	where on y Face	your body is	s the rash? (cho	ose all that apply)
	Head			
	Neck			
	Mouth			
	Lips or o	ral mucosa		
	Trunk			
	Arms			
	Legs			
	Palms of	f hands		
	Soles of	feet		



Perianal
Other locations
f other, please specify
Totaler, preuse speeting
[FOR INTERVIEWER] Any evidence of ocular involvement (ocular lesions, keratitis, conjunctivitis, eyelid lesions)? Yes No Unknown
FOR INTERVIEWER] Has this individual been diagnosed with any acute infections other than monkeypox during this current illness/or within the last three weeks? (e.g., gonorrhea, chlamydia, syphilis, HSV, other STI, varicella)  Yes No Unknown
f yes, please specify infections
FOR INTERVIEWER] What is the individual's HIV status? HIV Positive HIV Negative Unknown
f HIV positive, was the individual's viral load undetectable when it was last checked? Yes No Unknown
Does the individual have any known immunocompromising conditions (excluding HIV) or take mmunosuppressive medications? Immunocompromising conditions can include organ transplants, stem cell transplants, and active cancer. Certain medicines like chemotherapy, biologic therapies, and steroids can also weaken the immune system.  Yes No Unknown
f yes, describe the associated condition or treatment
Has the individual been hospitalized for monkeypox? Yes No Unknown
f yes, what was the reason for the hospitalization? (choose all that apply)  Breathing problems requiring mechanical ventilation
Breathing problems not requiring mechanical ventilation
Treatment for secondary infection  Pain control
Disseminated disease
Exacerbation of underlying condition (e.g. autoimmune or skin condition)
Other

Sensitive but Unclassified

6/30/2022 Page 9 of 10

Genitals



If other, specif	fy:	
Individual's m	ost recer	t admission date to the hospital for the condition covered by the investigation:
Individual's m	ost recen	t discharge date from the hospital for the condition covered by the investigation:
_	_	the individual currently receiving HIV pre-exposure prophylaxis?
Yes	No	Unknown
Are you currer	ntly preg	nant?
Yes	No	Unknown
Are you curren	ntly breas	stfeeding?
Yes	No	Unknown
[FOR INTERVIE	EWER] Pl	ease use this space to include any additional notes or comments.
[		,